ArticleCureus2025
Effects of Small Extracellular Vesicles Derived From Mesenchymal Stromal Cells on Acute Kidney Injury: A Rat Ischemia-Reperfusion Model.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Neutrophil-derived Microvesicles Regulate DNA Methylation of theSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Multifunctional Applications of Extracellular Nanovesicles for Acute Kidney Injury and Renal Fibrosis; a Mini Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are membrane-bound vesicles, containing nucleic acids, proteins, lipids, amino acids, and metabolites, used for intercellular communication. Several studies indicate that treatment with EVs derived from mesenchymal stromal cells (MSCs) has beneficial effects in acute kidney injury (AKI). MSCs derived from human Wharton's jelly are relatively non-immunogenic with no MHC class II expression and can serve as a viable source for treating human diseases. The aim of this study was to evaluate the effect of EVs derived from human cord tissue-derived MSCs on ischemic/reperfusion (I/R)-induced AKI. A rat I/R-induced AKI model was used, and a total of 33 rats were used in the study. Rats underwent unilateral nephrectomies with simultaneous clamping of the contralateral kidney for 60 minutes, followed by reperfusion. The treatment group received human MSC-derived small EVs, from a single donor, or placebo, and after 48 hours, the rats were sacrificed. Blood was used to evaluate renal function and the inflammatory cascade. Kidneys were taken for histopathologic and inflammation examinations. The EV-treated group significantly improved their renal function compared to the placebo group. Mean creatinine was 1.0 mg/dL in the EV-treated group versus 5.4 mg/dL in the placebo, p=0.005. With respect to the intrarenal inflammatory response, the EV-treated group significantly increased its anti-inflammatory cytokine interleukin-10 levels and attenuated the complement activation compared to the placebo. Perinatal tissue-derived EVs are potentially beneficial for clinical use since they can overcome many safety concerns related to stem cell use. Further clinical trials are needed to better assess these EVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.